Hospital News and Research

RSS

Overcoming challenges to health law implementation at federal, state levels

The Centers for Medicare & Medicaid Services is central to implementing the health law, which leads to questions about its capabilities and resources. Meanwhile, states await a final rule on health exchanges.

12 Mar 2012

Simple device for disinfecting stethoscopes

According to the Centers for Disease Control and Prevention (CDC) 1,900,000 people contract infections in hospitals, (Hospital Acquired Infections - HAIs) every year and well over 99,000 die as a result; more deaths than from AIDS, breast cancer and auto accidents combined.

12 Mar 2012

ESMO welcomes EC proposal to streamline access to medicines

The European Society for Medical Oncology (ESMO) welcomes the recent proposal by the European Commission aimed at streamlining the process and shortening the timeline surrounding national decisions on pricing drugs and reimbursement of payment made for medicines. This initiative, says ESMO, will facilitate patient access to innovative treatments on an EU-wide level.

12 Mar 2012

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

Former 'legal high' even more popular after UK ban

The former 'legal high' mephedrone is even more popular than it was shortly after it was banned by the UK government, according to a survey of London club-goers published in the Journal of Substance Use today.

12 Mar 2012

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.

12 Mar 2012

Sweco, ÅF sign joint contract with Skanska Healthcare for NKS in Solna

The engineering consultancies Sweco and ÅF have signed a joint contract with Skanska Healthcare AB for planning and design of the New Karolinska Hospital in Solna, NKS.

12 Mar 2012

Top-line results from Inviragen's INV21 Phase 1 trial on HFMD

Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.

12 Mar 2012

Researchers identify genetic signature for eosinophilic esophagitis

Researchers have identified a genetic signature for a severe, often painful food allergy – eosinophilic esophagitis – that could lead to improved diagnosis and treatment for children unable to eat a wide variety of foods.

12 Mar 2012

Many children with life limiting conditions have been underestimated

The number of children with conditions such as muscular dystrophy, neurodegenerative disorders or severe cerebral palsy who are surviving into adulthood has been underestimated, a new study shows.

12 Mar 2012

AMGA presents Medical Group Preeminence Award to VMMC

The American Medical Group Association today presented the Medical Group Preeminence Award to Virginia Mason Medical Center (VMMC), a health system based in Seattle, WA. The presentation took place at the AMGA 2012 Annual Conference, being held March 8-10 at the Manchester Grand Hyatt.

12 Mar 2012

HSS summit: Current classification system for osteoarthritis is inadequate

A recent summit that brought together international multidisciplinary experts has provided a foundation for addressing what is the leading cause of disability in the United States: osteoarthritis.

12 Mar 2012

New insight into causes of childhood pneumonia

The scientific journal Clinical Infectious Diseases has released its March Special Supplement focusing entirely on the research design of and pilot data from the Pneumonia Etiology Research for Child Health (PERCH) Project, which seeks to identify the causes of pneumonia among the world's most vulnerable populations.

12 Mar 2012

ICAP releases results from HPTN 064 Women's HIV Seroincidence Study

ICAP at Columbia University's Mailman School of Public Health is part of a network of research organizations that jointly released results, finding that HIV infection rates of black women living in certain parts of the U.S. are higher than previously estimated for black adolescent and women living in the U.S.

12 Mar 2012

Tranylcypromine shows promise against AML

A retinoid called all-trans retinoic acid (ATRA), which is a vitamin A-derivative, is already used successfully to treat a rare sub-type of acute myeloid leukemia (AML), however this drug has not been effective for the more common types of AMLs.

12 Mar 2012

HIPK2 regulator protein plays a crucial role in kidney fibrosis

Researchers from Mount Sinai School of Medicine have identified a regulator protein that plays a crucial role in kidney fibrosis, a condition that leads to kidney failure. Finding this regulator provides a new therapeutic target for the millions of Americans affected by kidney failure. The research is published in the March 11 issue of Nature Medicine.

12 Mar 2012

Sientra’s breast implant approved by the U.S. FDA

The implant, manufactured by Santa Barbara-based Sientra, can be used for breast tissue reconstruction for women of any age and for breast augmentation in women 22 or older. The approval resulted from three years of clinical studies on almost 1,800 patients. Tightening of the area around the implant, re-operation, implant removal, uneven appearance and infection were some of the complications experienced during the study. Sientra is required to continue studies on the implant's long-term safety, effectiveness and risks of rare diseases under the approval.

12 Mar 2012

Epidemic bacteria can damage mucins to enter and infect a body part

Boston, MA- Scientists from the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear and affiliate of Harvard Medical School, have found for the first time that a bacterial pathogen can literally mow down protective molecules, known as mucins, on mucus membranes to enter and infect a part of the body.

12 Mar 2012

APTA honors Women & Infants physical therapist with Elizabeth Noble Award

Wendy Baltzer-Fox, PT, DPT, GCS, WCS, of Cranston, supervisor of Women's Health Physical Therapy Services at Women & Infants Hospital of Rhode Island, has been presented with the Elizabeth Noble Award from the Section on Women's Health American Physical Therapy Association.

12 Mar 2012

Middle aged ignoring health messages on alcohol consumption

A new survey finds that adults aged 45 and over are more than three times as likely to drink alcohol almost every day as those under 45. This could mean that the middle aged population is ignoring the serious health risks associated with excessive drinking. The age disparity is most pronounced among women. Those aged 65 and over are 12 times more likely than those aged between 16 and 24 to drink on a near-daily basis according to data from the Office for National Statistics (ONS).

11 Mar 2012